The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
Misapplication of the guideline can put patient health and safety at risk.
The first generic naloxone nasal spray to treat opioid overdose has received approval from the US Food and Drug Administration.
An initial prescription of opioids for 4 to 7 days for the management of acute pain in the primary care setting was found to be sufficient.
Researchers found data to support psychological treatments to reduce the number of headaches and the headache index.
Many providers stopped initiating opioid therapy from July 2012 to December 2017.
In a draft report issued December 28, 2018 by the US Department of Health and Human Services-sponsored Pain Management Best Practices Inter-Agency Task Force, recommendations for a multidisciplinary approach to pain management were formulated.
Mindfulness-based cognitive therapy may represent a feasible and efficacious treatment for chronic low back pain.
The FDA has granted marketing clearance for eNeura’s single-pulse transcranial magnetic stimulation (sTMS) device for use in patients ≥12 years for the acute and prophylactic treatment of migraine.
Demand for naloxone is inelastic, with 1% increase in price resulting in 0.27% drop in sales
High-flow oxygen was found to be effective for cluster headaches, with less complications than seen with triptans.
Soldiers with low optimism had increased odds of reporting new back pain, joint pain, headaches.
Slump stretching may be beneficial to individuals with low back pain — based on very low to moderate quality evidence — according to a meta-analysis published in Pain Medicine. Slump stretching is achieved when sitting in a slouched position (ie, with thoracic and lumbar flexion and a posterior pelvic tilt) and actively flexing one’s cervical spine as far…
Conventional approaches to treatment of opioid-induced constipation include the use of treatment modalities that address non-opioid-related constipation as well as new medications that target the OIC mechanism of action.
Substantial, conclusive evidence of therapeutic efficacy found for 85.5% of qualifying conditions.
At 1 month, no significant difference seen in positive outcomes for treatment vs control.
Prescribers receiving opioid-specific payments prescribed 8784 more opioid daily doses per year.
Buprenorphine-naloxone may be more cost-effective than extended-release naltrexone as first-line treatment for opioid use disorder.
As the government shutdown drags in to its second month, physicians who treat opioid use disorders are being backed against a wall.
Opioids may only provide limited benefits for the management of chronic noncancer pain and may be associated with a greater risk for vomiting.